Adidas Superstar Discount
and other complications. Kalydeco slows the disease's progression and eases breathing. Its list price is $311,000 a year, but Vertex says most patients pay $50 per month. In December, the foundation sold its royalty rights on Kalydeco and other treatments developed by Vertex for $3. 3 Adidas Superstar Discount billion to speed up new research by Vertex, Pfizer and others. A second drug awaits approval, and Vertex is developing others.
ne third to one half, and approval is nearly assured. Big drugmakers do Adidas Superstar Camo
, Bristol Myers Squibb Co. , Celgene Corp. , Novartis AG and Novo Nordisk Adidas Superstar Gray
not disclose how much they invest in rare diseases. The returns can be huge, though. Pfizer Inc. made $3. 53 billion last year selling rare disease treatments, not counting its 10 cancer drugs for patients with specific genetic mutations. By 2019, 34 rare disease drugs could have annual sales exceeding $1 billion each, according to a forecast by research firm GlobalData. Other companies leading in the rare disease field include Baxter International Inc. , Bayer Corp.
, which spent 11 years screening 200,000 possibilities to find the best drug to test. The result was Kalydeco, approved in 2012 for 1,650 patients with a specific mutation. Kalydeco is the first drug to target the cause, not just symptoms, of cystic fibrosis, which causes sticky mucus to clog the lungs, triggering frequent infections Adidas Superstar Shoes Pink
The company hopes to have treatments for roughly 90 percent of patients by around 2020.
A/S. One financial model for rare diseases is the groundbreaking "venture philanthropy" pioneered by the Cystic Fibrosis Foundation, which funded early research on four key medicines for the genetic disease. Those drugs and better care raised average life expectancy from 10 years in the 1960s to 41 today. Over the years, the foundation raised millions through walkathons, gala dinners, golf tournaments and the like. With drug companies still not biting, it turned to paying for specific research projects. Since 2000, the foundation has committed $150 million to Vertex Pharmaceuticals Inc.